(Q34286350)

English

Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

0 references

author name string

Holland C Detke

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Fangyi Zhao

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Michael M Witte

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

publication date

30 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

51

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403915

6 July 2018

Olanzapine pamoate for the treatment of schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403915

6 July 2018

Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403915

6 July 2018

Long-acting injectable antipsychotics: focus on olanzapine pamoate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403915

6 July 2018

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403915

6 July 2018

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403915

6 July 2018

Olanzapine versus other atypical antipsychotics for schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403915

6 July 2018

Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403915

6 July 2018

Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403915

6 July 2018

Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403915

6 July 2018

Partial compliance in schizophrenia and the impact on patient outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403915

6 July 2018

Unanswered questions in schizophrenia clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403915

6 July 2018

Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403915

6 July 2018

Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403915

6 July 2018

A rating scale for extrapyramidal side effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403915

6 July 2018

A rating scale for drug-induced akathisia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403915

6 July 2018

Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-12-51

21 January 2018

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-12-51

21 January 2018

An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403915

28 October 2018

Effect sizes for interpreting changes in health status.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403915

28 October 2018

Attitudes of psychiatrists toward antipsychotic depot medication

1 reference

https://pubmed.ncbi.nlm.nih.gov/22646847

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22646847

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching

1 reference

https://pubmed.ncbi.nlm.nih.gov/22646847

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Knowledge about antipsychotic long-acting injections: bridging that gap

1 reference

https://pubmed.ncbi.nlm.nih.gov/22646847

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22646847

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The depot paradox

1 reference

https://pubmed.ncbi.nlm.nih.gov/22646847

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-244X-12-51

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34286350&oldid=2196463044"